Considering Metabolic Parameters and Weight Gain Associated With the Use of an Adjunctive Atypical Antipsychotic to Antidepressants for the Treatment of Major Depressive Disorder (MDD)

03/10/2025

Atypical antipsychotics can be associated with changes in metabolic parameters and weight gain in patients receiving adjunctive treatment to antidepressants for major depressive disorder (MDD). This video reviews the data on metabolic and weight changes from key clinical trials to help healthcare providers understand the potential impact.

Watch the bipolar I disorder video here and the schizophrenia video here.

This resource is intended for educational purposes only and is intended for US healthcare professionals. Healthcare professionals should use independent medical judgment. All decisions regarding patient care must be handled by a healthcare professional and be made based on the unique needs of each patient.

VRLR-US-00016-MC, V1.0
Approved 02/2025
AbbVie Medical Affairs

Andrew Cutler, MD

Clinical associate professor of psychiatry at State University of New York Upstate Medical University in Syracuse, New York, and chief medical officer of the Neuroscience Education Institute in Carlsbad, California

Roger McIntyre, MD, FRCPC

Professor of psychiatry and pharmacology at the University of Toronto and a practicing clinical psychiatrist

Considering Metabolic Parameters and Weight Gain Associated With the Use of an Adjunctive Atypical Antipsychotic to Antidepressants for the Treatment of Major Depressive Disorder (MDD)

More from the series:

Specialties

Events

Year Round Education

HMP Global Products